Search

everythinglearnresearchcommunity

for

Search:↓

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

A user from France is seeking ways to obtain oral minoxidil in the EU without a prescription, as local doctors are hesitant to prescribe it. Suggestions include visiting Spain for a prescription, ordering online, or consulting doctors in other EU countries like Portugal.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

The user shared impressive hair regrowth results after one year using oral finasteride and minoxidil spray, despite skepticism from some about the authenticity of the progress. The user experienced minimal side effects, such as an itchy scalp, and emphasized the importance of consistent use for maintaining results.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The user is using RU58841, finasteride, dutasteride, and minoxidil to slow down aggressive hair loss but is still experiencing hair shedding due to high testosterone levels. They plan to use ostarine to lower testosterone and prevent hair loss while maintaining muscle mass, and will continue using the other treatments.

Natural vitamins like pumpkin seed oil, saw palmetto, and ecklonia cava are discussed for their potential to lower DHT levels. They may work similarly to finasteride but are significantly weaker.

There is concern about a potential ban on finasteride and dutasteride in the EU, with users discussing the impact on hair loss treatment. Some suggest alternative treatments or express skepticism about the likelihood of a ban.

The user is dissatisfied with the results of using 0.3% finasteride and 6% minoxidil for hair thinning and is considering a topical treatment combining finasteride, dutasteride, minoxidil, melatonin, caffeine, and latanoprost. Another user suggests that high topical concentrations can lead to systemic exposure and recommends using oral dutasteride and microdosing topical finasteride.

A user's hair loss treatment progress over the last 6 months using finasteride, minoxidil and dermarolling; other users have commented to ask questions or share their own experiences.

Piroctone olamine and ketoconazole are both effective for reducing dandruff and hair shedding, with potential benefits for hair thickness and scalp health. Piroctone olamine may be as effective or better than ketoconazole in certain conditions, yet it is often overlooked.

The conversation is about the legitimacy and affordability of ordering a Minoxidil response test from TrichoGene, an India-based company, as an alternative to Daniel Alain. The user is seeking feedback on whether TrichoGene is a reliable option.

A 33-year-old male has been using topical dutasteride and minoxidil twice daily, along with a 0.25 mm derma roller every five days, and is experiencing hair shedding but seeing progress. Some users suspect a hair transplant, while others praise the results.

The conversation discusses the uncertainty of the legitimacy of minoxidil products in the EU market and mentions baricitinib as an approved, but expensive alternative. A method to test for real minoxidil involves mixing it with bleach to see if it turns orange or brown.

The user Consistent-Gene1334 shared their positive results in regrowing hair by using topical minoxidil and oral finasteride. Other users in the conversation praised the results and discussed the effectiveness of these treatments for diffuse thinning.

Retinol or tretinoin may improve minoxidil absorption and effectiveness. The user is considering using The Ordinary's 1% retinol as tretinoin is hard to get in their country.

Hair loss treatments Finasteride and Dutasteride are discussed, with emphasis on their safety and effectiveness. Users share frustration about fear-mongering and side effect discussions, suggesting trust in scientific studies and FDA approval.

The user experienced significant hair regrowth after 5 months using finasteride, dutasteride, and oral minoxidil, despite initial side effects like erectile dysfunction, which resolved after switching from finasteride to dutasteride. The user reports full recovery of hair density and improved skin condition, though the right temple remains slightly recessed.

Mixing topical solutions like Morr F 10% (Minoxidil) and L'Oreal Seryoxyl (Stemoxydine) before application may not reduce their effectiveness. The goal is to apply treatments all at once instead of multiple times a day.

Users discussed their experiences with oral minoxidil and dutasteride for hair loss. Most reported positive results, including hair regrowth and improved hair quality, with minimal side effects.

The user is taking generic oral dutasteride, oral minoxidil, vitamin D, and uses daily shampoo, along with a healthy diet and regular gym exercise for hair loss. Workmates noticed improvement in the user's hair condition.

The user switched from finasteride to dutasteride and is seeking feedback on hair changes after 4 months. The current regimen includes oral dutasteride, oral minoxidil, and topical minoxidil.

User shared before and after photos of hair regrowth using Dutasteride 5x a week for 19 months. They experienced significant improvement and thanked others for their support.

Dutasteride caused persistent hair shedding and no improvement for 18 months, leading to a switch back to finasteride. The user also uses oral minoxidil and plans to focus on better scalp health.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

The user is using 5% Minoxidil, a 1 mm derma stamp, Vitamin D3, Zinc, and anti-dandruff shampoo for hair regrowth. They plan to consider DHT blockers like finasteride in the future.